Although BVT 948 may be targeting several phosphatases, it exhibits greater efficacy against some PTPs [52], including PTP1B (PTPN1) and SHP-2 (PTPN11), that are drug targets for cancer, diabetes and obesity [26]. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.